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Abstract
Blackwater fever was typically reported after quinine administration, although it is poor 
recognized in patients receiving artesunate. This case describes a blackwater fever in a 
non-immune patient after artesunate for severe malaria. It highlights the importance of 




Blackwater fever is defined as an  earlyacute  intravascular haemolysis associated with 
marked haemoglobinuria and occasionally renal injury, jaundice and fever in patients 
with malaria.  It  was a condition typically reported after the administration of a few 
doses of quinine administration for malaria treatment in non-immune patients living in 
Africa, classically associated with low parasitemia [1],; but it has been also described in 
immune population [2]. With the introduction of other drugs but quinine in the treatment 
of malaria, the incidence of blackwater fever has decreased [3]. It occurred in less than 
10%  of  the  participants  in  the  artesunate  arm  in  AQUAMAT  and  SEAQUAMAT 
studies,  but  without  significant  differences  with  quinine  [4,5].  HoweverA different 
scenario is, delayed haemolysis associated to artesunate, usually presented between day 
7 and day 21 after the start of the treatment; it  has been described in up to 25% of cases 
in some studies [6]. In this cases, haemolysis is probably caused by a delayed clearance 
of pitting erythrocytes [6]. This 
The present case report describes a blackwater fever syndrome in a non-immune patient 
early after  treatment  with  intravenous  artesunate  for  severe  Plasmodium falciparum 
malaria. 
Case presentation
A 57 years old Spanish male presented to a regional hospital in Spain with a 3 day 
history of fever, chills, sweating, headache and generalized arthralgia and myalgia after 
a trip to Guinea Conakri 10 days before symptoms started (September 2016).
The  patient  had  stayed  in  Conakri  city  for  six  months.  He  never  took  malaria 
prophylaxis and he did not travelled to rural areas. As a medical record the patient had 
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suffered from right retinal detachment associated to lens dislocation 18 years ago and 
had cervical hernias (C4-C7) without neurological complications. He was not taking any 
chronic medication and he did not have any allergies. No previous malaria history was 
recorded.
He  was  admitted  under  malaria  suspicion.  A  thick  blood  smear  revealed  a  4% 
Plasmodium falciparum parasite count.  After diagnosis, the patient was referred to the 
National Reference Centre, Hospital Clinic of Barcelona, during the same day. At the 
time of admission he did not present with any other conditions defining severe malaria 
than the parasite count above 2.5% in a non-immune patient. On examination the patient 
was stable and the physical examination was normal with the exception of slight mental 
confusion.  The  patient  was  admitted  to  an  intermediate  care  unit  and  intravenous 
artesunate was started. After the second dose (180 mg = 2.4 mg per patient kilogram per 
dose), 12 hours after the first one, the patient started with intense coluria (coke-like 
color) (Figure 1). Urine analyses showed no red cells but haemoglobinuria. At that time 
parasitemia was 0,  and parameters of haemolysis  appeared,  with increased levels of 
bilirrubin and lactate dehydrogenase (peak day 2), and reduced levels of hemoglobin 
and  haptoglobin  (Table  1).  Thus  the  diagnosis  of  intravascular  haemolysis  with 
haemoglobinuria (or blackwater fever) was established. Other causes or triggers of the 
haemolysis than artesunate were ruled out: serologic tests for dengue and leptospira as 
well as blood cultures and direct Coombs test were negative; there was no evidence of 
thalassemia, he had normal glucose-6 phosphate dehydrogenase activity and he did not 
have past history of splenectomy. Afterwards, intravenous artesunate was stopped and 
the  treatment  was  switched  to  atovaquone-proguanil  (250  mg  atovaquone/100mg 
proguanil  per  tablet,  4  tablets  per  day)  for  3  more  days  without  complications  and 
progressive clinical recovery. The patient did not need blood transfusions or suffered of 
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renal  impairment.  Two  days  after  the  beginning  of  the  hemolytic  event,  clinical 
pneumonia,  without  final  microbiological  confirmationdiagnosis, was diagnosed with 
clinical and radiological criteria, and the patient received ceftriaxone for 5 days and 
levofloxacin for 10 days.  Haemoglobinuria disappeared by day 5 of admission with 
slow recovery of  hemolytic  parameters.  The patient  was discharged after  7  days  of 
admission. 
The patient was completely recovered after four weeks and no signs of delayed 
hemolysis were observed.
Discussion and Conclusions
Herein  we  have  described  the  case  of  a  patient  with  hemolytic  anemia  and 
hemoglobinuria in the context of malaria under treatment with artesunate (blackwater 
fever). The acute haemolysis in our case could be due to malaria itself. Plasmodium can 
induce haemolytic anaemia due to the inflammatory cascade added to the rupture of 
paratisitized  erythrocytes,  parasitized or not[7]. However, the fact that the hemolysis 
started after two doses of artesunate makes the drug suspicious of a relevant role in its 
development.  Artesunate can induce oxidant haemolysis, although in lesser degree than 
quinine  or  mefloquine [8].  Artesunate  also  changes  the  erythrocyte  membrane 
increasing its fragility[  8]. Accordingly, artesunate has been  recently  related to acute 
haemolysis with haemoglobinuria in a Plasmodium knowlesi Malayan patient[9] as well 
as a  Cambodian patient after artesunate derivatives in an uncomplicated Plasmodium 
falciparum  infection[190],  besides  the  previously  commented  description  in  larger 
studies  amongst  immune  population  in  the  past  (AQUAMAT[4]  and 
SEAQUAMAT[5]).
6
Patients  with  splenectomy,  thalassemia  or  low  glucose-6  phosphate  dehydrogenase 
activity have more risk to suffer severe haemolysis  during Plasmodium infection[10], 
although our patient did not have any  known  underlying condition.  Other  described 
triggers of haemolysis that our patient presented are high parasitemia, which is related 
with  blackwater  fever  in  murine  models[11],  and is the  presence  of  a  bacterial 
infection[9], although pneumonia was diagnosed after the beginning of the haemolysis. 
The clinical consequences in the case described were mild but highlights the importance 
to  monitor  urine  as  well  as  hemolytic  parameters  in  severe  malaria  after  artesunate 
treatment, especially in splenectomized or thalassemic patients, in order to avoid renal 
impairment or severe anaemia.
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Day 1 Day 2 Day 3 Day 4 Day 5 Day 8
Total Bilirrubin 
mg/dL
4.7 3.1 3.1 1.3
Indirect bilirrubin 
mg/dL
2.2 0.9 0.4 0.6
LDH U/L 721 2359 2005 951 721 618
Haemoglobin g/L 155 147 147 125 128 118
Hematocrit % 43 43 41 36 35 36




Table 1. Change in laboratory parameters during admission in Hospital Clinic of 
Barcelona. LDH: lactate dehydrogenase
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